Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

or orexin receptor 2 (OX2R). These receptors regulate sleep and wakefulness, stress responses, and appetite. Drugs like Belsomra block the activity of these neurotransmitters by attaching to the ...

The orally-active drug was granted breakthrough status ... could strike at the underlying pathology of the condition. Orexin antagonists, meanwhile – such as Eisai's Dayvigo (lemborexant ...

For instance, daridorexant, a novel orexin receptor antagonist, has shown promise in improving sleep outcomes and daytime functioning in individuals with insomnia disorder. Clinical trials ...